Comparative Pharmacology
Head-to-head clinical analysis: BYVALSON versus TEVETEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYVALSON versus TEVETEN.
BYVALSON vs TEVETEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
Selective angiotensin II receptor type 1 (AT1) antagonist, blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II.
160 mg orally once daily.
400-800 mg orally once daily; can be divided twice daily if needed for adequate blood pressure control.
None Documented
None Documented
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Terminal elimination half-life is approximately 7-8 hours in patients with normal renal function, supporting once-daily dosing.
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Renal (approximately 60% as unchanged drug) and biliary/fecal (approximately 40%).
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker